Home / CDx/IVD Products / NGS-Based Assays / Detection of Homologous Recombination Repair Defect
Detection of Homologous Recombination Repair Defect

HRDetectCDx Panel is an HRD score detection Panel independently developed by MEDx Translational Medicine. It is based on 41,000+ high-quality single nucleotide polymorphism sites (SNPs) screened by ChinaMap database of 10,000 individuals. By analyzing heterozygosity Deletion (Loss of Heterozygosity, LOH), Telomere Allelic Imbalance (TAI), and Large-scale State Transitions (LST), etc, the Genomic Instability Score (GenomicInstability Score, GIS) can be calculated. HRDetectCDx Panel is divided into mutant version, scoring version, and full foreign version, which meets the detection needs from different customers. 

Detection significance

a.HRD is present in approximately 50% of patients with high-grade serous ovarian cancer.

b.The incidence of HRD-positive patients is 2-3.5 times that of BRCA1/2-positive patients alone, which helps to find more benefit groups of PARP inhibitors.

c.Patients with high HRD values are more sensitive to PARP inhibitors than those with low HRD values.

d.Patients with high HRD values benefit from platinum-based chemotherapy regimens more than those with low HRD values.

Detection advantage


① Design a gene list with reference to the University of Washington consensus, NCCN guidelines and other institutional guidelines, and comprehensively include 85 related genes.

② Referring to the ChinaMap database of 10,000 individuals in China, screening 41,000+ high-quality SNPs loci in the Chinese population.


The scoring algorithm optimized for the Chinese population simultaneously analyzes the three genomic instability indicators of LOH, TAI and LST to provide a comprehensive GIS score.


Ultra-high sequencing depth, and low-frequency sites are not missed.

High quality

Imported raw materials are used for testing to ensure the quality of testing from the source.


Cancer patient:Patients with breast cancer (triple negative breast cancer), ovarian cancer, prostate cancer, pancreatic cancer and peritoneal cancer etc.

Patients on medication: PARP Inhibitor medication patients

Personalized treatment of patients:Individualized treatment of patients with platinum-based chemotherapy or other homologous recombination inhibitors


CDx Panel

HRR detect

GIS detect

Other functions





Mutant version

85 genes,System + Germline






Graded version

85 genes,System + Germline



Full version

WES,System + Germline


If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.

1. Customized or bulk orders of IVD/CDx products.

2. Get a quote for IVD/CDx products

3. Become our distributor

4. Get customized pharmaceutical service solutions

5.Learn more about our technology and R&D